Quality of life, respiratory symptoms, and health care utilization 1 year following outpatient management of COVID-19: a prospective cohort study

Rachel K. Lim1, Ryan Rosentreter2, Yushi Chen3, Rahul Mehta4, Graham McLeod2, Miranda Wan2, Jonathan D. Krett2, Yasamin Mahjoub2, Angela Lee2, Ilan Schwartz4, Luanne Metz2, Lawrence Richer5, Eric Smith2, Michael D. Hill2, ALBERTA HOPE COVID-19 Collaborators* & Aravind Ganesh*2

The long-term impact of COVID-19 among those with mild infections is not well characterized. Among 81 adults who completed online assessments at 3- and 12-months following infection, quality of life scores did not significantly improve over time. Among 62 subjects who also completed telephone interviews, respiratory symptoms or exercise limitation were reported by 42% at a median follow-up of 387 days (IQR 251–402 days). Those with persistent respiratory symptoms scored lower on the EQ-5D visual analog score compared to those without. Persistent respiratory symptoms were associated with a lower likelihood of full-time employment at 1 year (aOR 0.09, 95%CI 0.01–0.91; P = 0.041). In an adjusted linear regression, persistent respiratory symptoms (P = 0.037) and female sex (P = 0.016) were both independent risks for increased visits to a primary care provider. This cohort study demonstrates that respiratory symptoms are frequent at 1 year following COVID-19 and more importantly, are associated with negative impacts on employment, quality of life, and health care utilization. Further research is needed to determine the pathophysiology and risk factors for persistent symptoms as well as optimal management strategies to improve the level of functioning and quality of life.

To date, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 500 million infections globally1. Although many individuals with coronavirus-19 disease (COVID-19) have a complete recovery, a significant proportion of survivors experience long-term sequelae following the acute infection, loosely termed post COVID-19 condition or “long COVID”2,3. The natural course and burden of symptoms are poorly understood, particularly as a majority of studies focus on individuals who were hospitalized for COVID-192. We prospectively assessed the 1-year outcomes among non-hospitalized survivors of COVID-19 using both a telephone and online questionnaire-based assessment.

Community-dwelling individuals with symptomatic, lab-confirmed SARS-CoV-2 infection in Alberta, Canada were recruited to a randomized controlled trial studying the efficacy of hydroxychloroquine (HCQ) in preventing severe disease between April and May 2020. In a province with a population of approximately 4.4
Participants reported a median of 2 visits (IQR 0 to 5) to their family physician for any reason since their COVID-19 diagnosis, participants were asked to rate their quality of life using the EQ-5D-3L using an online link. Participants were phoned at 12 months post-COVID-19 for a structured interview about persistent symptoms or symptoms thought to be related to COVID-19, exercise ability, the number of visits to their family physician or emergency department since recovery, and employment status. Provincial healthcare records were reviewed to capture any hospitalizations or emergency department visits. Wilcoxon Rank Sum was used to compare continuous variables, Fisher’s exact test to compare proportions, and multivariable logistic regressions for adjusted comparisons of proportions. EQ-5D-3L ratings were converted to EQ-5D index scores using the Canadian value set. All analyses were performed using STATA 16.1 (StataCorp LP, College Station, USA).

Among 84 participants who completed at least one assessment, the median time from COVID-19 diagnosis to final follow-up was 387 days (IQR 251 to 402 days). The mean age was 46.5 years (standard deviation 11.3) and 43% were male. Mean body mass index (BMI) was 29.5 kg/m² (standard deviation 8.2). Cough was the most common reported symptom (n = 42, 79%) during acute COVID-19, followed by fever (n = 21, 40%), and dyspnea (n = 15, 28%). Hypertension (n = 13, 25%) and diabetes (n = 13, 25%) were the most common baseline comorbidities, while asthma was present in at least 17% of participants. Sixty-three subjects reported being either a former smoker or never smoker, while 11 were active smokers at baseline. Among 62 participants who completed the telephone symptom assessment at 1 year, 12 (19%) reported dyspnea and 13 (21%) reported cough at their 1-year follow-up. Using the modified Medical Research Council (mMRC) dyspnea scale, a quarter of those with dyspnea reported an mMRC grade 2 or higher. If participants reported that their exercise tolerance had not returned to baseline yet, then this was considered as the presence of exercise intolerance. Persistent respiratory symptoms including reduced exercise tolerance were reported in 42% of the cohort at the final follow-up.

Participants reported a median of 2 visits (IQR 0 to 5) to their family physician for any reason since their initial COVID-19 diagnosis. Individuals with persistent respiratory symptoms visited their family physician more frequently compared to those without (median number of visits 3 versus 1, p = 0.0291). Although there was no control group in this study, it is worth noting that historical controls from a national survey reported that 54% of Canadians visited their family physician once a year or less in 2018. Twelve individuals accounted for 15 visits to the emergency department (ED) since their COVID-19 diagnosis. There was no difference in ED visits between those with persistent respiratory symptoms and those without (p = 0.711).

As for daily function, 18 out of 62 (30%) stated that their exercise ability had not yet returned to their baseline prior to having COVID-19. In addition, patients reporting persistent respiratory symptoms were less likely to have full-time employment at 1-year follow-up compared to those without symptoms, even after accounting for pre-COVID-19 employment status (adjusted OR 0.09, 95%CI 0.01–0.91, p = 0.041). The EQ-5D-3L scores at 3 months and 12 months for 81 subjects are presented in Table 1. There was no statistically significant difference

| Domain of EQ-5D-3L | 3 month follow-up N = 81 | 12 month follow-up N = 81 | P-value |
|--------------------|--------------------------|---------------------------|---------|
| Mobility           |                          |                           |         |
| No problems        | 67 (83%)                 | 69 (85%)                  | 0.83    |
| Some problems or unable to walk | 14 (17%)               | 12 (15%)                  |         |
| Selfcare           |                          |                           |         |
| No problems        | 80 (99%)                 | 78 (96%)                  | 0.062   |
| Some problems or unable to wash or dress | 1 (1%)                 | 3 (4%)                    |         |
| Usual activities   |                          |                           |         |
| No problems        | 67 (83%)                 | 69 (85%)                  | 0.83    |
| Some problems or unable to perform | 14 (17%)               | 12 (15%)                  |         |
| Pain               |                          |                           |         |
| No pain or discomfort | 48 (59%)                | 52 (64%)                  | 0.63    |
| Some or extreme pain or discomfort | 33 (41%)                | 29 (36%)                  |         |
| Anxiety and depression |                    |                           |         |
| Not anxious or depressed | 55 (68%)              | 55 (68%)                  | 1.00    |
| Moderately or extremely anxious or depressed | 26 (32%)            | 26 (32%)                  |         |
| Median EQ-5D-3L scores (IQR) | 6 (5–7)             | 6 (5–7)                   | 0.08    |
| Mean EQ-5D Index Scorea (standard deviation) | 0.859 (0.159) | 0.881 (0.147)          | 0.06    |
| EQ-VAS (0–100), mean (standard deviation) | 76.3 (18.9) |                           |         |

Table 1. Quality of life status (EQ-5D-3L) at 3 months and 12 months after COVID-19. EQ-5D-3L, EuroQol Group Association five-domain, three-level questionnaire; EQ-VAS, EuroQol visual analogue scale. *Health state index scores calculated from a Canadian value set.
in scores between follow-ups. The median EQ-5D-3L scores were higher (indicating worse quality of life) among those with persistent respiratory symptoms compared to those without (p = 0.0278).

Adjusting for age and sex, a prior or current history of smoking was associated with 4.7-fold higher odds of having persistent respiratory symptoms compared to never-smokers (aOR 4.71, 95%CI 1.12–19.8, p = 0.035). A prior diagnosis of asthma or the presence of cough or dyspnea at the time of acute COVID-19 illness was not associated with persistent respiratory symptoms at 1 year. Patients with persistent respiratory symptoms were less likely to rate their quality of life satisfactorily (defined pragmatically as 75–100 on the EQ-5D visual analog scale, aOR 0.16, 95%CI 0.03–0.94, p = 0.043) after adjusting for age, sex, BMI, burden of initial symptoms, and prior treatment with HCQ. In a linear regression adjusted for age, BMI, prior HCQ treatment, and initial symptom burden, persistent respiratory symptoms (p = 0.037) and female sex (p = 0.016) were associated with increased visits to their family physician.

Conclusions
There is growing evidence of considerable morbidity and reduced level of function among those with “mild” acute infections who did not require hospitalization.8,9,10 This is concerning given that delayed recovery may lead to prolonged absence from work, school, or other activities, as well as a reduced quality of life. Our findings suggest that persistent respiratory symptoms including dyspnea, cough, and exercise intolerance were frequent at 1 year following infection by SARS-CoV-2 and that this was associated with lower employment levels, reduced quality of life and greater utilization of primary health care. Interestingly, the cohort’s median EQ-5D-3L scores did not differ between measurements. Although there was no significant difference between time points, this highlights the enduring impact of post COVID-19 condition, as many continued to report significant levels of anxiety, depression, pain, and mobility difficulties at 12 months.

Whereas our study has several strengths, including a prospective cohort design nested within a randomized controlled trial, with laboratory-confirmed COVID-19 for all participants, limitations include a relatively small sample, loss to follow-up, and a lack of a control group without COVID-19. Given that participants had to agree to be contacted for research and were already involved in a trial, there is a chance of recruitment bias. This study is one of a few to prospectively assess patients with milder outpatient illness at greater than a year following infection, providing useful information for health care providers managing "long COVID". Further research is needed to determine the pathophysiology and risk factors for persistent symptoms as well as optimal management strategies to improve the level of functioning and quality of life.

Ethics approval and consent to participate. Granted by the Conjoint Health Research Ethics Board at the University of Calgary (REB20-0790). Informed patient consent was obtained.

Data availability
The datasets analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Received: 3 January 2022; Accepted: 22 July 2022
Published online: 29 July 2022

References
1. Johns Hopkins COVID-19 dashboard. https://coronavirus.jhu.edu/map.html (Accessed July 2022).
2. National Institute for Health and Care Excellence COVID-19 rapid guideline: managing the long-term effects of COVID-19. https://www.nice.org.uk/guidance/ng188 (Accessed 18 Aug 2021).
3. World Health Organization. A clinical case definition of post COVID-19 conditions by a Delphi consensus, 6 October 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (Accessed 25 Oct 2021).
4. Schwartz, I. et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: A randomized controlled trial. CMAJ Open 9(2), E693–E702. https://doi.org/10.9778/cmaoj.20210069 (2021).
5. EuroQol Group. EuroQol group new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990).
6. Bansback, N., Tsuchiya, A., Brazier, J. & Anis, A. Canadian valuation of EQ-5D health states: Preliminary value set and considerations for future valuation studies. PLoS ONE 7(2), e31115. https://doi.org/10.1371/journal.pone.0031115 (2012).
7. Fletcher, C. M. et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 2, 257 (1959).
8. IPSOS Foundation. Global views on healthcare—2018. https://www.ipsos.com/sites/default/files/ct/news/documents/2018-07/global-views-on-healthcare-2018-ipsos-global-advisor.pdf.
9. Lund, L. C. et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: A Danish population-based cohort study. Lancet Infect. Dis. 10, S1473-3099(20)30021–5 (2021).
10. Beetsie, J. et al. Persistent symptoms in adult patients one year after COVID-19: A prospective cohort study. Clin. Infect. Dis. 5, ciaa611 (2021).

Acknowledgements
A full list of members and their affiliations appears in the Supplementary Information.

Author contributions
R.L., A.G., M.D.H., L.M., L.R., and I.S. were responsible for study conceptualization and methodology. R.R., Y.C., R.M., G.M., M.W., J.D.K., Y.M., A.L. and A.G. performed data collection and management. R.L. and A.G. performed data analysis. R.L. wrote the initial draft and all authors reviewed and approved the final version.
Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-17243-7.

Correspondence and requests for materials should be addressed to A.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

ALBERTA HOPE COVID-19 Collaborators

Rachel K. Lim¹, Luanne Metz², Michael D. Hill², Aravind Ganesh², Lawrence Richer⁴ & Ilan Schwartz⁵